Literature DB >> 15186439

Effect of Bifidobacterium longum ingestion on experimental salmonellosis in mice.

A M Silva1, F H F Barbosa, R Duarte, L Q Vieira, R M E Arantes, J R Nicoli.   

Abstract

AIMS: The effect of lactic acid bacteria on the immune system is well established under normal conditions and generally by in vivo determinations, but few data are available, in vivo, during an infectious challenge. The objective of this study was to obtain data on the putative protective role of bifidobacteria upon challenge with an intestinal pathogen. METHODS AND
RESULTS: The effect of oral treatment with Bifidobacterium longum Bb46 on intragastric challenge with Salmonella Typhimurium was studied. Faecal bacterial levels were determined in gnotobiotic (GN) mice and mortality, histopathology (intestines, liver), immunoglobulin levels (IgM, IgG, IgG1, IgG2a) and cytokine production (IFN-gamma, IL-10) were determined in conventional (CV) mice. Conventional mice received 0.1 ml probiotic milk (10(8) CFU) daily, 10 days before the oral pathogenic challenge (10(2) CFU). Then, probiotic treatment was continued until the end of the experiment. Probiotic treatment in germ-free mice consisted of a single dose at the beginning of the experiment. Control groups were treated with sterile skim milk and submitted to the same procedure. A higher survival (40%) was observed for probiotic-treated animals when compared with the control group (0%). This protective effect was confirmed by the histopathological and morphometric data. However, S. Typhimurium population levels in the faeces were similar among control and probiotic-treated groups. During the challenge with S. Typhimurium, a decrease in IFN-gamma and IgG2a productions was observed in probiotic-treated mice.
CONCLUSIONS: The protective effect against the pathogenic challenge may be due to a reduced inflammatory response, mediated by the probiotic treatment, but not to a population antagonism. SIGNIFICANCE AND IMPACT OF THE STUDY: Results suggest that dietary supplementation with B. longum could provide benefits against enteric infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186439     DOI: 10.1111/j.1365-2672.2004.02265.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  19 in total

1.  Diversity of the type I-U CRISPR-Cas system in Bifidobacterium.

Authors:  Liuyang Ou; Jinzhao Long; Yanli Teng; Haiyan Yang; Yuanlin Xi; Guangcai Duan; Shuaiyin Chen
Journal:  Arch Microbiol       Date:  2021-04-09       Impact factor: 2.552

2.  Innate mechanisms for Bifidobacterium lactis to activate transient pro-inflammatory host responses in intestinal epithelial cells after the colonization of germ-free rats.

Authors:  Pedro A Ruiz; Micha Hoffmann; Silke Szcesny; Michael Blaut; Dirk Haller
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

3.  Interference of Bifidobacterium choerinum or Escherichia coli Nissle 1917 with Salmonella Typhimurium in gnotobiotic piglets correlates with cytokine patterns in blood and intestine.

Authors:  A Splichalova; I Trebichavsky; V Rada; E Vlkova; U Sonnenborn; I Splichal
Journal:  Clin Exp Immunol       Date:  2010-12-13       Impact factor: 4.330

Review 4.  Enteric pathogen exploitation of the microbiota-generated nutrient environment of the gut.

Authors:  Kristie M Keeney; B Brett Finlay
Journal:  Curr Opin Microbiol       Date:  2011-01-05       Impact factor: 7.934

5.  A five-strain probiotic combination reduces pathogen shedding and alleviates disease signs in pigs challenged with Salmonella enterica Serovar Typhimurium.

Authors:  Pat G Casey; Gillian E Gardiner; Garrett Casey; Bernard Bradshaw; Peadar G Lawlor; P Brendan Lynch; Finola C Leonard; Catherine Stanton; R Paul Ross; Gerald F Fitzgerald; Colin Hill
Journal:  Appl Environ Microbiol       Date:  2007-01-19       Impact factor: 4.792

6.  Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118.

Authors:  Sinéad C Corr; Yin Li; Christian U Riedel; Paul W O'Toole; Colin Hill; Cormac G M Gahan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-24       Impact factor: 11.205

7.  Characteristic Immune Response in Peyer's Patch Cells Induced by Oral Administration of Bifidobacterium Components.

Authors:  Yusuke Nakanishi; Akira Hosono; Yasuhiro Hiramatsu; Teiji Kimura; Ryo Nakamura; Shuichi Kaminogawa
Journal:  Cytotechnology       Date:  2005-01       Impact factor: 2.058

8.  Antiviral activity of Bifidobacterium adolescentis SPM1005-A on human papillomavirus type 16.

Authors:  Min-Kyeong Cha; Do-Kyung Lee; Hyang-Mi An; Si-Won Lee; Seon-Hee Shin; Jeong-Hyun Kwon; Kyung-Jae Kim; Nam-Joo Ha
Journal:  BMC Med       Date:  2012-07-12       Impact factor: 8.775

9.  Bifidobacterium infantis 35624 protects against salmonella-induced reductions in digestive enzyme activity in mice by attenuation of the host inflammatory response.

Authors:  Erin L Symonds; Caitlin O'Mahony; Susan Lapthorne; David O'Mahony; John Mac Sharry; Liam O'Mahony; Fergus Shanahan
Journal:  Clin Transl Gastroenterol       Date:  2012-05-10       Impact factor: 4.488

10.  Some putative prebiotics increase the severity of Salmonella enterica serovar Typhimurium infection in mice.

Authors:  Anne Petersen; Peter M H Heegaard; Anna L Pedersen; Jens B Andersen; Rikke B Sørensen; Hanne Frøkiaer; Sampo J Lahtinen; Arthur C Ouwehand; Morten Poulsen; Tine R Licht
Journal:  BMC Microbiol       Date:  2009-11-30       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.